Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.

Nearly half of all late-stage cancer trials that started in 2015 had an antibody component, and 2016 brings the first full survival data from pivotal multi-checkpoint antibody trials. We document the immuno-oncology surge in data.

Sanofi-Aventis’ multi-layered 10-year deal with the contract research organization Covance, announced September 30, 2010, is yet another sign of the pressure within Big Pharma to cut R&D costs even as it searches for new sources of innovation.